Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase 1 dose-escalation data, cash-runway forecasts, and share-based compensation tables often stretch Nuvalent鈥檚 disclosures far beyond 200 pages. Finding where the company reports trial enrollment numbers or how much dilution new equity raises might cause can feel like searching for a molecule in a lab beaker. If you have ever typed 鈥淣uvalent insider trading Form 4 transactions鈥� into Google, you already know the challenge. That complexity is why investors need Nuvalent SEC filings explained simply, without losing the nuance that drives valuation for a clinical-stage oncology company.
Stock Titan鈥檚 AI tackles the hard chemistry of regulatory language. Our engine turns each Nuvalent annual report 10-K simplified and every Nuvalent quarterly earnings report 10-Q filing into plain-English briefs that spotlight pipeline progress, R&D spend, and cash-burn trends. AG真人官方-time alerts push Nuvalent Form 4 insider transactions real-time to your dashboard, so you can see Nuvalent executive stock transactions Form 4 within minutes of EDGAR posting. Interactive modules map 8-K material events to specific trial milestones, letting you skim Nuvalent 8-K material events explained instead of scrolling line by line.
Want deeper context? Click into any filing and our AI highlights where option grants appear in a Nuvalent proxy statement executive compensation section, or generates side-by-side Nuvalent earnings report filing analysis across quarters. You will also find:
- Segmented R&D spend tied to ALK, ROS1, and HER2 programs
- Cash-runway projections based on the latest 10-Q
- Insider purchase patterns before data readouts
Understanding Nuvalent SEC documents with AI means less time decoding tables and more time deciding if the next kinase-inhibitor breakthrough fits your portfolio. AG真人官方-time updates, comprehensive coverage, and expert analysis鈥攁ll in one place.
Form 4 Overview 鈥� Nuvalent, Inc. (NUVL)
On 06/26/2025, Chief Development Officer Darlene Noci reported a series of option exercises and related open-market sales under a pre-arranged Rule 10b5-1 trading plan dated 11/18/2024.
- Option exercise: 4,000 Class A common shares were acquired via option exercise at an exercise price of $27.85 per share.
- Dispositions: The exact 4,000 shares were immediately sold in three blocks: 85 sh at a weighted average $77.38, 3,609 sh at $78.70, and 306 sh at $79.15. Aggregate proceeds approximate $311 k, implying a spread of roughly $50 per share over the exercise price.
- Post-transaction holdings: Noci鈥檚 direct ownership declined from 52,034 to 48,034 shares (-7.7%). She retains 138,329 stock options expiring 01/06/2033.
No other equity classes or derivative instruments were reported. All transactions were effected under a 10b5-1 plan, suggesting routine portfolio management rather than discretionary selling.
Nuvalent, Inc. (NUVL) 鈥� Form 4 insider transaction summary
Chief Scientific Officer Henry E. Pelish reported a series of option exercises and related open-market sales executed on 06/25/2025 and 06/27/2025 under a Rule 10b5-1 trading plan adopted on 11/01/2024.
- Options exercised (Code 鈥淢鈥�): 10,800 Class A shares in four tranches 鈥� 3,677 and 347 shares at a $27.85 strike (options granted 01/06/2023) and 4,953 and 1,823 shares at a $29.33 strike (options granted 03/01/2023).
- Shares sold (Code 鈥淪鈥�): 10,800 Class A shares at weighted-average prices of $79.87 (range $79.80-$79.92) on 06/25/2025 and $79.92 (range $79.80-$80.00) on 06/27/2025.
- Ownership impact: Pelish鈥檚 direct Class A common-stock holding remains unchanged at 63,101 shares after the paired exercise-and-sell transactions, indicating a cashless exercise structure.
- Remaining derivative holdings: 28,328 options at a $27.85 strike (expiring 01/06/2033) and 25,299 options at a $29.33 strike (expiring 03/01/2033) are still outstanding.
No new shares were added to, or removed from, insider ownership; the activity primarily generated liquidity while maintaining the existing equity stake. Investors typically view such neutral, plan-based sales as having limited informational content, though they can add modest selling pressure near the $80 trading level.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
